T. Evans

发表

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

H. Wakelee, D. Gandara, S. Ramalingam, 2017, The Lancet. Oncology.

Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC.

T. Evans, 2012, Anticancer research.

Discrepancies of assessments in a RECIST 1.1 phase II clinical trial – association between adjudication rate and variability in images and tumors selection

A. Guermazi, C. Klifa, T. Evans, 2018, Cancer Imaging.

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Sharyn I. Katz, K. Elenitoba-Johnson, W. Hwang, 2019, JAMA oncology.

The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.

N. Petrelli, R. Beart, N. Wolmark, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of chemotherapy in the management of advanced thymic tumors.

T. Lynch, T. Evans, 2005, Seminars in thoracic and cardiovascular surgery.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

M. Kris, V. Rusch, C. Azzoli, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined MTOR and autophagy inhibition

A. Alavi, D. Torigian, A. Troxel, 2014, Autophagy.

Adjuvant Cisplatin and Docetaxel for Non-small Cell Lung Cancer: The Hospital of the University of Pennsylvania Experience

J. Shrager, J. Cooper, C. Langer, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy in advanced non-small cell lung cancer.

T. Evans, 2005, Seminars in respiratory and critical care medicine.

Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).

A. Shaw, S. Gettinger, S. Ou, 2012 .

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.

C. Langer, R. Mick, R. Cohen, 2019, JAMA oncology.

Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.

C. Langer, R. Mick, R. Cohen, 2022, Clinical lung cancer.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Alona Muzikansky, Thomas J Lynch, Bruce E Johnson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors

P. Jänne, L. Sequist, T. Lynch, 2007 .

Defining High-Quality Palliative Care in Oncology Practice: An American Society of Clinical Oncology/American Academy of Hospice and Palliative Medicine Guidance Statement.

A. Abernethy, M. Broder, C. Shapiro, 2016, Journal of oncology practice.

Prospective study of proton‐beam radiation therapy for limited‐stage small cell lung cancer

C. Simone, A. Berman, C. Langer, 2017, Cancer.

DIAGNOSIS LUNG Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

M. Socinski, L. Sequist, S. Gettinger, 2013 .

Special topics in immunotherapy and radiation therapy: reirradiation and palliation.

D. Gomez, T. Evans, C. Ciunci, 2007, Translational lung cancer research.

Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non–Small Cell Lung Cancer Receiving Sequential Treatment

C. Simone, C. Langer, R. Rengan, 2016, American journal of clinical oncology.

E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC--Outcomes based on chemotherapy subsets.

H. Wakelee, D. Gandara, S. Ramalingam, 2016 .

Choosing Wisely in Oncology: Are We Ready For Value-Based Care?

M. Markham, D. Blayney, M. Jahanzeb, 2017, Journal of oncology practice.

Adjuvant radiotherapy for completely resected stage 2 thymoma

S. Singhal, J. Metz, J. Cooper, 2011, Cancer.

E13-05: Insights into thymic epithelial tumors: chemotherapy

T. Evans, 2007 .

SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

M. Kris, C. Azzoli, P. Jänne, 2014 .

Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer

C. Langer, T. Evans, S. Bagley, 2016 .

Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.

Sharyn I. Katz, C. Langer, D. Sterman, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications.

C. Langer, M. Corradetti, N. Mitra, 2011, International journal of radiation oncology, biology, physics.

Detection by 18F-FDG-PET/CT of upper extremity acute deep venous thrombosis.

A. Alavi, D. Torigian, T. Evans, 2011, Hellenic journal of nuclear medicine.

Is a cancer diagnosis a teachable moment for the patient’s relative who smokes?

C. Langer, F. Leone, R. Schnoll, 2013, Cancer Causes & Control.

Building a better therapy for stage IIIA non-small cell lung cancer.

T. Lynch, D. Mathisen, T. Evans, 2002, Clinics in chest medicine.

Palliative Care in Lung Cancer: When to Start

S. Dessain, T. Evans, Prianka Bhattacharya, 2018, Current Oncology Reports.

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

A. Troxel, D. Heitjan, K. Nathanson, 2014, Autophagy.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

C. Langer, A. Vachani, R. Cohen, 2017, Lung cancer.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

M. Mino‐Kenudson, J. Neal, H. Wakelee, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

M. Socinski, L. Sequist, S. Gettinger, 2013 .

Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

C. Langer, R. Mick, E. Carpenter, 2018, JCO precision oncology.

Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.

C. Langer, E. Carpenter, R. Cohen, 2017, Annals of translational medicine.

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer

C. Rudin, J. Nemunaitis, B. Halmos, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non–Small‐cell Lung Cancer

C. Langer, I. Blair, A. Vachani, 2017, Clinical lung cancer.

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.

C. Langer, C. Watt, R. Mick, 2013, Clinical lung cancer.

Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?

C. Langer, C. Watt, R. Mick, 2013, Lung cancer.

Emerging treatment options for patients with recurrent advanced thymic epithelial tumors

T. Evans, 2012, OncoTargets and therapy.

Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): The Expanded Access Protocol Experience at the University of Pennsylvania

J. Shults, J. Stevenson, M. L. Veronese, 2005, Cancer investigation.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Anil Vachani, Charu Aggarwal, Andrea B. Troxel, 2016, Clinical Cancer Research.

Peripheral Immune Cell Gene Expression Predicts Survival of Patients with Non-Small Cell Lung Cancer

Noor B. Dawany, A. Kossenkov, S. Albelda, 2012, PloS one.

Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.

C. Langer, J. Weiss, T. Evans, 2010, Clinical lung cancer.

Etirinotecan Pegol (NKTR‐102) in Third‐line Treatment of Patients With Metastatic or Recurrent Non–Small‐cell Lung Cancer: Results of a Phase II Study

W. Hwang, C. Langer, R. Cohen, 2017, Clinical lung cancer.

A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer

M. Socinski, T. Hensing, T. Stinchcombe, 2009, Cancer investigation.

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)

S. Ramalingam, A. Argiris, J. Schiller, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II randomized trial of carboplatin , paclitaxel , bevacizumab with or without cixutumumab ( IMCA 12 ) in patients with advanced non-squamous , non-small-cell lung cancer : a trial of the ECOG-ACRIN Cancer Research Group ( E 3508 )

S. Ramalingam, A. Argiris, J. Schiller, 2017 .

Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.

C. Simone, S. Hahn, A. Maity, 2019, JAMA oncology.

Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study.

C. Simone, C. Langer, M. Corradetti, 2015, Practical radiation oncology.

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy

C. Langer, A. Vachani, R. Cohen, 2015, Oncotarget.

P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC): Topic: IT

C. Langer, A. Vachani, R. Cohen, 2017 .

Complementary and alternative medicine use and benefit finding among cancer patients.

C. Langer, D. Valentine, J. Mao, 2013, Journal of alternative and complementary medicine.

Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional survey

C. Langer, S. Garland, T. Evans, 2014, Supportive Care in Cancer.

A phase II study of gefitinib in patients with advanced thyroid cancer.

Thomas J Lynch, R. Heist, J. Temel, 2008, Thyroid : official journal of the American Thyroid Association.

Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy

K. Syrigos, F. Shepherd, R. Ramlau, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Defining high-quality palliative care in oncology practice: An ASCO/AAHPM Guidance Statement.

A. Abernethy, M. Broder, C. Shapiro, 2015, Journal of Clinical Oncology.

Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial

Steven W. Johnson, P. O'dwyer, I. Vasilevskaya, 2004 .

Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.

G. Giaccone, G. Oxnard, A. Krivoshik, 2016 .

Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes.

Nandita Mitra, Jarod Finlay, Eli Glatstein, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response

M. Rosen, S. Hahn, A. Maity, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.

C. Langer, J. Kucharczuk, N. Mitra, 2012, International journal of radiation oncology, biology, physics.

Highlights from the Tenth World Conference on Lung Cancer.

T. Evans, 2004, The oncologist.

Recent Advances in the Treatment of Stage IIIA Lung Cancer

T. Lynch, T. Evans, 2003 .

The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited‐Stage Small‐Cell Lung Cancer

C. Simone, K. Cengel, C. Langer, 2017, Clinical Lung Cancer.

MET amplification (amp) as a resistance mechanism to osimertinib.

C. Azzoli, L. Sequist, A. Shaw, 2017 .

Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.

L. Sequist, M. Edelman, M. Tan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of PET Staging in Limited-Stage Small-Cell Lung Cancer

Nandita Mitra, Charles B Simone, Daniel A Pryma, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.

G. Giaccone, G. Oxnard, A. Krivoshik, 2015 .

Lung Cancer

M. Iannettoni, T. Lynch, T. Evans, 1999, The oncologist.

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

G. Giaccone, G. Oxnard, A. Krivoshik, 2017, Clinical Cancer Research.

Paraneoplastic microscopic polyangiitis presenting after thymectomy

M. Rosenbach, A. Sreih, A. Rubin, 2016, JAAD Case Reports.

Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.

A. Shaw, S. Ou, R. Salgia, 2012 .

Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.

D. Torigian, A. Troxel, C. Langer, 2017, Lung cancer.